acute leukemia
Conditions
Interventions
Experimental group:Autologous CIK treatment
Control group:Conventional treatment
Sponsors
Beijing Boren Hospital
Eligibility
Sex/Gender
All
Age
2 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with low-risk acute leukemia, who achieved first complete remission (CR) after chemotherapy and who had sustained complete remission (CCR) = 4 months (US NCCN 2015.2 standard); 2. The last chemotherapy, whole body radiotherapy is over 2 weeks; 3. Hemoglobin (Hb) = 80g/L, white blood cell count (WBC) = 2.5 × 10^9/L, platelet count = 50 ×10^9/L; 4. Age 2-70 years old; 5. The patient has the ability to self-knowledge and can sign informed and voluntary consent forms; 6. The patient or his client, the guardian of the child patient, joins the study after signing the informed and voluntary consent form.
Exclusion criteria
Exclusion criteria: 1. Intracranial hypertension or unconsciousness; 2. Symptomatic heart failure or severe arrhythmia; 3. Respiratory failure; 4. with other types of malignant neoplasms; 5. T-lymphocytic acute leukemia; 6. Diffuse vascular internal coagulation; 7. Serum creatinine and / or urea nitrogen = 1.5 times the normal value; 8. Serum total bilirubin = 1.5 times normal; 9. Sepsis or other uncontrollable infections; 10. Uncontrollable diabetes; 11. Severe mental disorders; 12. The WHO physical status classification is =3. 13. Those who are allergic to IL2. 14. Organ transplant recipients. 15. Pregnant and lactating women. Both the study group and the control patients must meet the inclusion criteria and do not meet the exclusion criteria. Each paired case must meet the following conditions: 1. The age difference does not exceed 3 years old; 2. Morphology, immunology, cytogenetics, genotyping at the time of initial diagnosis; 3. Clinical features at the time of initial diagnosis: including features of hepatosplenomegaly, extramedullary leukemia, and whether it is hyperleukocytic leukemia; 4. The time required to achieve complete remission (CR) is similar; 5. The number of chemotherapy courses, chemotherapy regimens and doses before the selection are similar; 6. Pre-selection CR status: including CCR time (CCR time before the selection is not more than 3 months), whether all extramedullary leukemia has occurred; 7. There are similar co-morbidities such as hepatitis C and hepatitis B.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SAFETY;Bone marrow and peripheral blood tumor cell ratio; | — |
Countries
China
Contacts
Public ContactTONG CHUNRONG
Beijing Boren Hospital
Outcome results
None listed